Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Mar 6

PMID 33673713

Citations 9

Authors

Bin Zhang

Jiamei Zou

Qiting Zhang

Ze Wang

Ning Wang

Shan He

Yufen Zhao

C Benjamin Naman

Affiliations

Soon will be listed here.

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K or Ca2+/calmodulin-dependent protein kinase, CAMKIII) is a new member of an atypical α-kinase family different from conventional protein kinases that is now considered as a potential target for the treatment of cancer. This protein regulates the phosphorylation of eukaryotic elongation factor 2 (eEF2) to restrain activity and inhibit the elongation stage of protein synthesis. Mounting evidence shows that eEF2K regulates the cell cycle, autophagy, apoptosis, angiogenesis, invasion, and metastasis in several types of cancers. The expression of eEF2K promotes survival of cancer cells, and the level of this protein is increased in many cancer cells to adapt them to the microenvironment conditions including hypoxia, nutrient depletion, and acidosis. The physiological function of eEF2K and its role in the development and progression of cancer are here reviewed in detail. In addition, a summary of progress for in vitro eEF2K inhibitors from anti-cancer drug discovery research in recent years, along with their structure-activity relationships (SARs) and synthetic routes or natural sources, is also described. Special attention is given to those inhibitors that have been already validated in vivo with the overall aim to provide reference context for the further development of new first-in-class anti-cancer drugs that target eEF2K.

Citing Articles

Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.

Debnath S, Debnath M, Ghosh A, Srivastava R, Omri A Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459028 PMC: 11510357. DOI: 10.3390/ph17101389.

Exploring Canine Mammary Cancer through Liquid Biopsy: Proteomic Profiling of Small Extracellular Vesicles.

Novais A, Tamarindo G, Melo L, Balieiro B, Nobrega D, Dos Santos G Cancers (Basel). 2024; 16(14).

PMID: 39061201 PMC: 11275101. DOI: 10.3390/cancers16142562.

Multi-Channel smFRET study reveals a Compact conformation of EF-G on the Ribosome.

Johnson J, Steele J, Lin R, Stepanov V, Gavriliuc M, Wang Y bioRxiv. 2024; .

PMID: 38328191 PMC: 10849647. DOI: 10.1101/2024.01.27.577133.

RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.

Scholl S, Bello Roufai D, Cherif L, Kamal M J Gynecol Oncol. 2023; 34(5):e74.

PMID: 37668079 PMC: 10482580. DOI: 10.3802/jgo.2023.34.e74.

Can endocan serve as a molecular "hepatostat" in liver regeneration?.

Yazici S, Gedik M, Leblebici C, Kosemehmetoglu K, Gunaydin G, Dogrul A Mol Med. 2023; 29(1):29.

PMID: 36849916 PMC: 9972723. DOI: 10.1186/s10020-023-00622-9.

References

Li T, Wang N, Zhang T, Zhang B, Sajeevan T, Joseph V . A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors. Mar Drugs. 2019; 17(9). PMC: 6780990. DOI: 10.3390/md17090493. View

Bellail A, Tse M, Song J, Phuphanich S, Olson J, Sun S . DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med. 2009; 14(6A):1303-17. PMC: 2891654. DOI: 10.1111/j.1582-4934.2009.00777.x. View

Arora S, Yang J, Kinzy T, Utsumi R, Okamoto T, Kitayama T . Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 2003; 63(20):6894-9. View

Yamaguchi H, Matsushita M, Nairn A, Kuriyan J . Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell. 2001; 7(5):1047-57. DOI: 10.1016/s1097-2765(01)00256-8. View

Parmer T, Ward M, Hait W . Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ. 1997; 8(3):327-34. View

Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N . Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem Biol Drug Des. 2019; 93(5):760-786. DOI: 10.1111/cbdd.13486. View

Pyr Dit Ruys S, Wang X, Smith E, Herinckx G, Hussain N, Rider M . Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase. Biochem J. 2012; 442(3):681-92. PMC: 3286862. DOI: 10.1042/BJ20111530. View

Proud C . Regulation and roles of elongation factor 2 kinase. Biochem Soc Trans. 2015; 43(3):328-32. DOI: 10.1042/BST20140323. View

Ryazanov A, Shestakova E, Natapov P . Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature. 1988; 334(6178):170-3. DOI: 10.1038/334170a0. View

10.

Liu J, Voisin V, Wang S, Wang D, Jones R, Datti A . Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 2014; 6(12):1542-60. PMC: 4287974. DOI: 10.15252/emmm.201404402. View

11.

McCracken M, Miraglia L, McKay R, Strobl J . Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol Cancer Ther. 2003; 2(3):273-81. View

12.

Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T . Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol. 2008; 180(11):7175-83. DOI: 10.4049/jimmunol.180.11.7175. View

13.

Akter Z, Ahmed F, Tania M, Khan M . Targeting Inflammatory Mediators: An Anticancer Mechanism of Thymoquinone Action. Curr Med Chem. 2019; 28(1):80-92. DOI: 10.2174/0929867326666191011143642. View

14.

Clark A, West K, Blumberg P, Dennis P . Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003; 63(4):780-6. View

15.

Yang J, Yang J, Iannone M, Shih W, Lin Y, Hait W . Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res. 2001; 61(10):4010-6. View

16.

Grant C . Regulation of translation by hydrogen peroxide. Antioxid Redox Signal. 2010; 15(1):191-203. DOI: 10.1089/ars.2010.3699. View

17.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

18.

Zhao Y, Tian Y, Liu L, Zhan J, Hou X, Chen X . Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma. Drug Des Devel Ther. 2018; 12:2655-2663. PMC: 6120571. DOI: 10.2147/DDDT.S169952. View

19.

Arafa E, Zhu Q, Shah Z, Wani G, Barakat B, Racoma I . Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 2010; 706(1-2):28-35. PMC: 3037029. DOI: 10.1016/j.mrfmmm.2010.10.007. View

20.

Bircan H, Gurbuz N, Pataer A, Caner A, Kahraman N, Bayraktar E . Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 2018; 124:31-39. DOI: 10.1016/j.lungcan.2018.07.027. View